Electronic Nose for Diagnosis of Neurodegenerative Diseases Via Breath Samples
|ClinicalTrials.gov Identifier: NCT01291550|
Recruitment Status : Unknown
Verified September 2010 by Rambam Health Care Campus.
Recruitment status was: Recruiting
First Posted : February 8, 2011
Last Update Posted : February 8, 2011
The diagnosis of neurodegenerative conditions and ADHD still mostly relies on clinical symptoms as there are no validated, inexpensive, and simple bio- markers available yet. The purpose of this study is to deliver a proof-of-concept for novel biomarkers to identify neurodegenerative conditions and ADHD based on breath testing.
Alveolar breath will be collected from healthy volunteers, patients with extrapyramidal conditions, patients diagnosed with dementia and from ADHD subjects. The discriminative power of a tailor-made Nanoscale Artificial Nose (™NA-NOSE) containing an array of six nanomaterial-based sensors will be tested. Discriminant factor analysis will be applied to the NA-NOSE signals in order to detect statistically significant differences between the sub-populations, and classification success will be estimated using leave-one-out cross-validation. The identification of NA-NOSE patterns will be supported by analyzing the chemical composition of the breath using gas-chromatography in conjunction with mass-spectrometry (GC-MS).
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||300 participants|
|Study Start Date :||September 2010|
Patients with parkinsonism and patients with dementia
Subjects diagnosed with ADHD
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01291550
|Cognitive Neurology, Rambam Medical Center||Recruiting|
|Haifa, Israel, 31096|
|Contact: Judith Aharon-Peretz, M.D 97248543190 email@example.com|
|Contact: Michal Levavi, MA.RN|
|Principal Investigator: Judith Aharon-Peretz, M.D|